Ursodeoxycholic acid sodium
Cat. No.：YN322452
| 产品名称: | Ursodeoxycholic acid sodium |
| CAS No.: | 2898-95-5 |
| Chemical Name: | (3α,5β,7β)-3,7-dihydroxy-cholan-24-oic acid, monosodium salt |
| Synonyms: | 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium |
| 分子量: | 414.6 |
| 分子式: | C24H39O4 • Na |
| SMILES: | [O-]C(CC[C@@H](C)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C)=O.[Na+] |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Ursodeoxycholic acid (Ursodeoxycholate) sodium 是由肠道细菌转化 (cheno)脱氧胆酸而产生的一种次级胆汁酸，是肠道屏障完整性的关键调节因子，对脂质代谢至关重要。Ursodeoxycholic acid sodium 作为信号分子，通过与胆汁酸激活的受体相互作用发挥作用，包括G蛋白偶联的胆汁酸受体5 (TGR5，GPCR19) 和法尼酯X受体 (FXR)。Ursodeoxycholic acid sodium 可用于多种肝脏和胃肠道疾病的研究。具有口服活性。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Dawson, P.A., and Karpen, S.J.Intestinal transport and metabolism of bile acidsJ. Lipid Res.56(6),1085-1099(2015)
Chiang, J.Y.L.Bile acid metabolism and signaling in liver disease and therapyLiver Res.1(1),3-9(2017)
Deo, A.K., and Bandiera, S.M.3-Ketocholanoic acid is the major in vitro human hepatic microsomal metabolite of lithocholic acidDrug Metab. Dispos.37(9),1938-1947(2009)
Kim, R.B., Leake, B., Cvetkovic, M., et al.Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activityJ. Pharmacol. Exp. Ther.291(3),1204-1209(1999)
Rodrigues, C.M.P., Fan, G., Ma, X., et al.A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbationJ. Clin. Invest.101(12),2790-2799(1998)
